查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968488

短肠症候群市场－全球产业规模、份额、趋势、机会、预测：依药物类别、通路、地区和竞争格局划分，2021-2031年

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球短肠症候群市场预计将从 2025 年的 8.5402 亿美元成长到 2031 年的 12.6237 亿美元，复合年增长率为 6.73%。

该市场涵盖治疗生物製药和药物，例如生长激素和类升糖素肽-2类似物，旨在改善接受过广泛小肠切除术患者的营养吸收并促进肠道适应。推动该市场成长的主要因素是需要手术介入和持续管理的严重胃肠道疾病（例如肠系膜缺血和克隆氏症）的盛行率不断上升。此外，旨在减少对肠外营养依赖、改善生活品质和临床疗效的标靶治疗的研发也促进了该市场的发展。

市场概览
预测期 2027-2031
市场规模：2025年 8.5402亿美元
市场规模：2031年 1,262,370,000 美元
复合年增长率：2026-2031年 6.73%
成长最快的细分市场 线上销售
最大的市场 北美洲

根据美国肠外经肠营养学会 (ASPN) 2024 年的数据，全球短肠症候群相关肠道功能障碍的盛行率估计为每 10 万成年人 0.12 至 2.74 例。儘管有这样的需求，市场面临着许多障碍，包括先进药物和长期治疗的高昂费用。这种沉重的经济负担造成了巨大的报销难题，尤其是在医疗基础设施尚不完善的情况下，限制了患者的就医途径，并有效地阻碍了这些新型医疗方案的广泛应用。

市场驱动因素

新型GLP-2类似物疗法的商业化和应用正在从根本上改变全球短肠症候群市场，减少患者终身依赖肠外营养的情况。这些先进的生物製药模拟天然肠道激素，促进肠道适应，并显着降低维持生命所需的静脉输液频率和输液量。这些治疗方法的快速普及凸显了临床上迫切需要找到解决方案来减轻与长期使用导管相关的併发症。这一发展动能体现在主要市场参与者的成功上，例如武田药品工业株式会社。该公司在2024年5月发布的「2023财年业绩报告」中指出，其旗舰产品Gatex/Levestiv在2023财年的销售额达到7.96亿美元。这主要得益于较高的治疗维持率和患者可近性的提高。

同时，新一代疗法的强劲临床开发平臺正在推动市场发展，其中长效製剂的推出减轻了患者每日註射的负担。製药公司正致力于研发每週一次的治疗方案，与目前的治疗标准相比，这些方案有望提高患者的依从性和生活品质。作为这项进展的佐证，Ironwood Pharmaceuticals在2024年2月的新闻稿中宣布，其在研药物apraglutide与治疗前方案相比，每週肠外营养支持量减少了25.5%。这些创新正瞄准高价值的市场区隔。 Ironwood预计，到2024年，欧洲、日本和美国约有18,000名成年人患有伴随肠道功能障碍的短肠症候群，并认为这些新兴治疗方法蕴藏着巨大的市场机会。

市场挑战

先进药物治疗和长期疗法的高昂费用是全球短肠症候群市场成长的主要障碍。慢性肠外营养和特殊生物製药的高昂价格导致医保支付方面临诸多阻力，往往导致严格的报销通讯协定和频繁的拒付。这种经济负担迫使医疗机构仅在最难治或严重的病例中使用新疗法，阻碍了产品的推广。因此，在医疗基础设施欠发达、公共资金不足以支持此类昂贵终身治疗的地区，市场扩张举步维艰。

保险公司和病患的这种经济负担与市场扩张受限直接相关。 2024年，PAN基金会报告称，在其短肠症候群经济援助计划下，已向符合条件的患者提供了18,200美元的首批津贴。这凸显了一个现实：即使是受保人用户也面临高昂的自付费用。如此沉重的经济负担会阻碍患者继续治疗，并限制创新医疗方案的商业性应用，从而抑制整个产业的获利能力。

市场趋势

家庭肠外营养服务的扩展正将长期照护的重心从临床环境转移到住宅环境，旨在提高患者的生活品质并降低医院相关成本。这一趋势使慢性肠道功能障碍的管理分散化，使患者能够在获得必要营养支持的同时维持日常生活。然而，供应链不稳定和营运成本上升威胁着这种模式的永续性。根据美国家庭输液协会于2025年8月发布的一份白皮书，2016年至2024年间，家庭经肠营养产品的製备成本预计将以每年75.4%的速度增长，这将为寻求扩展这些基本服务的机构带来沉重的经济负担。

同时，拓展儿童适应症已成为一项重要的策略驱动力，製药公司正扩大其临床目标，以惠及先前服务不足的儿童患者群体。透过儿童用药的监管核准，製造商正在建立早期疗育通讯协定，以减轻短肠症候群对儿童发育的长期影响，这种策略不同于以往仅关注成人的策略。这种向更年轻族群的策略转变正在带来实际的经济效益。根据 PharmaLive 2025 年 10 月的一篇报导，武田製药的 Gatex/Levestiv 在 2024 财年的销售额成长了 22.6%，达到 9.66 亿美元。这一成长动能显然归功于儿童适应症拓展所带来的需求成长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球短肠症候群市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物分类（GLP-2、麸酰胺酸、生长激素）
    • 分销管道（医院药房、线上销售、零售药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美短肠症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲短肠症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区短肠症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲短肠症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美短肠症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球短肠症候群市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Dentsply Sirona Inc.
  • Emmaus Life Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • OxThera AB
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19143

The Global Short Bowel Syndrome Market is projected to expand from USD 854.02 Million in 2025 to USD 1262.37 Million by 2031, registering a CAGR of 6.73%. This market encompasses therapeutic biologics and pharmaceuticals, such as growth hormones and glucagon-like peptide-2 analogs, aimed at improving nutrient absorption and facilitating intestinal adaptation in patients who have experienced significant small bowel resection. The primary catalyst for this growth is the rising prevalence of serious gastrointestinal conditions, including mesenteric ischemia and Crohn's disease, which require surgical intervention and ongoing management. Furthermore, the market is being bolstered by the creation of targeted therapies designed to decrease reliance on parenteral nutrition, thereby offering enhanced quality of life and better clinical results.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 854.02 MIllion
Market Size 2031USD 1262.37 MIllion
CAGR 2026-20316.73%
Fastest Growing SegmentOnline Sales
Largest MarketNorth America

According to data from the American Society for Parenteral and Enteral Nutrition in 2024, the diagnosed prevalence of intestinal failure associated with short bowel syndrome was estimated at 0.12 to 2.74 per 100,000 adults worldwide. Despite this demand, the market faces a major obstacle in the form of prohibitive costs linked to advanced pharmacological treatments and long-term therapies. This high financial burden results in significant reimbursement challenges and restricts patient access, particularly within developing healthcare infrastructures, which effectively constrains the widespread adoption of these novel medical solutions.

Market Driver

The commercialization and adoption of novel GLP-2 analog therapies is fundamentally transforming the Global Short Bowel Syndrome Market by lessening patient dependence on lifelong parenteral nutrition. These advanced biologics simulate natural gut hormones to encourage intestinal adaptation, which significantly lowers the frequency and volume of intravenous fluids needed for survival. The rapid uptake of these treatments highlights a critical clinical need for solutions that reduce complications related to chronic catheter use. This momentum is reflected in the success of major market players; for instance, Takeda's May 2024 'FY2023 Full Year Results' reported that sales for its leading therapy, Gattex/Revestive, hit $796 million for the fiscal year 2023, fueled by high adherence rates and broadened patient access.

Simultaneously, a robust clinical pipeline of next-generation therapeutics is driving the market forward by introducing long-acting formulations designed to remove the burden of daily injections. Pharmaceutical developers are focusing on once-weekly dosing regimens expected to enhance patient compliance and quality of life relative to current care standards. As evidence of this progress, Ironwood Pharmaceuticals announced in a February 2024 press release that their investigational drug apraglutide achieved a 25.5 percent relative decrease in weekly parenteral support volume. These innovations target a high-value niche; Ironwood estimated in 2024 that Short Bowel Syndrome with Intestinal Failure affects approximately 18,000 adults across Europe, Japan, and the U.S., presenting a concentrated opportunity for these emerging treatments.

Market Challenge

The exorbitant costs associated with advanced pharmacological treatments and long-term therapy act as a major barrier to the growth of the Global Short Bowel Syndrome Market. The high price tags for chronic parenteral nutrition and specialized biologics cause significant friction with payers, often leading to stringent reimbursement protocols and frequent claim denials. This financial toxicity compels healthcare providers to restrict the prescription of novel therapies to only the most refractory or severe cases, effectively stifling product uptake. Consequently, the market struggles to expand in regions with developing healthcare infrastructures where public funding is inadequate to support such premium, lifelong treatments.

This economic burden on insurers and patients directly correlates with limited market expansion. In 2024, the PAN Foundation reported that its financial assistance program for Short Bowel Syndrome provided an initial grant of $18,200 to eligible patients, underscoring the substantial out-of-pocket costs faced even by those with insurance. Such a high level of financial liability discourages patient adherence and restricts the commercial reach of innovative medical solutions, thereby capping revenue potential throughout the sector.

Market Trends

The expansion of home-based parenteral nutrition services is shifting long-term care priorities from clinical settings to residential environments, aiming to enhance patient quality of life and cut hospital-related costs. This trend decentralizes the management of chronic intestinal failure, enabling patients to maintain their daily routines while receiving necessary nutritional support. However, the sustainability of this model is threatened by supply chain instability and rising operational expenses. A white paper released by the National Home Infusion Association in August 2025 noted that the cost of preparing home parenteral nutrition formulations rose by a compounded 75.4 percent between 2016 and 2024, placing significant economic strain on providers trying to scale these essential services.

Concurrently, a strategic focus on pediatric label expansions is emerging as a key growth driver, with pharmaceutical companies broadening their clinical targets to include the underserved pediatric population. By obtaining regulatory approvals for children, manufacturers are establishing early intervention protocols designed to mitigate the long-term developmental effects of short bowel syndrome, differentiating their strategies from purely adult-focused approaches. This pivot toward younger demographics is delivering tangible financial gains; according to an October 2025 PharmaLive article, sales for Takeda's Gattex/Revestive increased by 22.6 percent to $966 million in fiscal year 2024, a growth trajectory explicitly attributed to demand from pediatric indication label expansions.

Key Market Players

  • Dentsply Sirona Inc.
  • Emmaus Life Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • OxThera AB
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Short Bowel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short Bowel Syndrome Market, By Drug Class

  • GLP-2
  • Glutamine
  • Growth Hormone

Short Bowel Syndrome Market, By Distribution Channel

  • Hospital Pharmacies
  • Online Sales
  • Retail Pharmacies

Short Bowel Syndrome Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short Bowel Syndrome Market.

Available Customizations:

Global Short Bowel Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short Bowel Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (GLP-2, Glutamine, Growth Hormone)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Online Sales, Retail Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Short Bowel Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Short Bowel Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Short Bowel Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Short Bowel Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Short Bowel Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Short Bowel Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Short Bowel Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Short Bowel Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Short Bowel Syndrome Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Short Bowel Syndrome Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Short Bowel Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Short Bowel Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Short Bowel Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Short Bowel Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Short Bowel Syndrome Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Short Bowel Syndrome Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Short Bowel Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Short Bowel Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Short Bowel Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Short Bowel Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Short Bowel Syndrome Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Short Bowel Syndrome Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Short Bowel Syndrome Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Short Bowel Syndrome Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Short Bowel Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dentsply Sirona Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Emmaus Life Sciences, Inc.
  • 15.3. Merck & Co., Inc.
  • 15.4. Novartis AG
  • 15.5. OPKO Health, Inc.
  • 15.6. OxThera AB
  • 15.7. Pfizer Inc.
  • 15.8. Swedish Orphan Biovitrum AB
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer